Abstract
Background/aimsVoretigene neparvovec (VN) is the first and only subretinal gene therapy approved by the Food and Drug Administration and European Medicines Agency. Real-world application has started in 2018 in patients...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have